Protalix Biotherapeutics Inc Stock TEL AVIV STOCK EXCHANGE
Stocks
US74365A1016
Pharmaceuticals
| Market Cap | 219M 0 192M 182M 166M 310M 21B 312M 2.17B 842M 10.73B 823M 805M 34.49B | P/E 2026 * |
11.3x | P/E 2027 * | 54.4x |
|---|---|---|---|---|---|
| Enterprise Value | 219M 0 192M 182M 166M 310M 21B 312M 2.17B 842M 10.73B 823M 805M 34.49B | EV / Sales 2026 * |
2.67x | EV / Sales 2027 * | 3.3x |
| Free-Float |
96.12% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Protalix Biotherapeutics Inc
| 1 day | -1.13% |
| Manager | Title | Age | Since |
|---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 59 | 2019-06-29 |
Gilad Mamlok
DFI | Director of Finance/CFO | 57 | 2025-08-23 |
Ori Kalid
CTO | Chief Tech/Sci/R&D Officer | - | 2024-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Amos Bar Shalev
BRD | Director/Board Member | 73 | 2008-06-30 |
Aharon Schwartz
BRD | Director/Board Member | 83 | 2014-10-31 |
Dror Bashan
BRD | Director/Board Member | 59 | 2019-06-29 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.13% | -11.89% | - | - | 219M | |
| +0.13% | +2.65% | +65.61% | +114.28% | 1,055B | |
| +0.20% | +0.46% | +52.60% | +69.24% | 654B | |
| -0.29% | +0.14% | +20.96% | +70.93% | 467B | |
| -0.85% | +0.98% | +41.29% | +44.38% | 348B | |
| +0.71% | +4.08% | +22.24% | +29.51% | 275B | |
| +1.23% | +0.42% | +14.57% | +12.13% | 258B | |
| +2.11% | +7.51% | +52.89% | +55.37% | 224B | |
| +0.83% | +0.55% | +35.99% | +101.70% | 187B | |
| 0.00% | -10.14% | -29.94% | -60.30% | 171B | |
| Average | +0.21% | +0.74% | +30.69% | +48.58% | 404.26B | |
| Weighted average by Cap. | +0.02% | +1.32% | +41.54% | +67.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 82.16M 0 72.09M 68.09M 62.05M 116M 7.87B 117M 815M 316M 4.02B 308M 302M 12.93B | 66.48M 0 58.34M 55.1M 50.21M 93.99M 6.37B 94.66M 659M 255M 3.26B 250M 244M 10.46B |
| Net income | 19.63M 0 17.23M 16.27M 14.83M 27.76M 1.88B 27.95M 195M 75.41M 961M 73.71M 72.12M 3.09B | 3.79M 0 3.33M 3.14M 2.87M 5.36M 364M 5.4M 37.63M 14.57M 186M 14.24M 13.94M 597M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
